SPI-1005 Ebselen 200mg Capsule x2 for Ototoxicity

"SPI-1005 Ebselen 200mg Capsule x2 has been rated a 2 on the safety scale by Power, as this is still only in Phase 2 and there are no findings to support its efficacy yet."

"Presently, 5 clinical trials are being conducted in order to assess the efficacy of SPI-1005 Ebselen 200mg Capsule x2. 1 is currently in Phase 3. Despite there being a primary base for these studies located in Winston-Salem, North carolina, 41 different medical centres are hosting related investigations."

"Sadly, this research study has already closed its enrollment process. It was initially posted in July 2017 and last updated in December 2022. If one is searching for alternative trials, there are presently 140 studies recruiting patients with cystic fibrosis and 5 clinical trials actively enrolling participants to test SPI-1005 Ebselen 200mg Capsule x2."

"Research on SPI-1005 Ebselen 200mg Capsule x2 began in 2017, when its first clinical trial was funded by Sound Pharmaceuticals Inc. Subsequent to this investigation of 80 participants, the drug obtained phase 2 approval and is now subject to 5 active studies across two nations with a total of 24 centres involved."

"This research endeavour has ended its search for participants. It was initially posted on the 21st of July 2017 before being updated lastly on December 7th 2022. If you are still interested in finding clinical trials, 140 studies for cystic fibrosis and 5 concerning SPI-1005 Ebselen 200mg Capsule x2 are currently recruiting patients."